Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth
Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiological linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Key examples are rheumatoid arthritis (RA), psoriasis, lupus and ankylosing spondylitis.
Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and mobility loss, and have a negative impact on quality of life.
Generally, disease-modifying anti-rheumatic drugs (DMARD) - a highly genericized class of systemic small molecule based agents - are used in the first-line treatment of these diseases. These are supplemented in many cases with shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.
However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, which began with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal antibodies (mAb), which are highly commercially successful due to their widespread use and high cost.
Although the patents for many of these mAbs have either already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $57.7 billion in 2015 to $75.4 billion in 2022, at a compound annual growth rate (CAGR) of 3.88%. This is due to practical and regulatory barriers to entry for biosimilars that are not present for small molecule generics, and a moderately strong late-stage pipeline. There is a large pharmaceutical pipeline for immunology, consisting of 2,054 products in active development. The majority of pipeline products (73%) are in the early stages of development, at either the Preclinical or Discovery stages, but 96 (5%) are in Phase III.
The key market players, namely AbbVie, Johnson & Johnson, Roche, Amgen and Pfizer, are forecast to maintain their strong market shares throughout the forecast period, despite the fact that many of the approaching patent expiries - especially that of adalimumab, marketed by AbbVie, and Remicade, marketed by Johnson & Johnson - will affect these companies directly.
The report “Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth” focuses on four key indications within immunology: Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Psoriasis and Inflammatory bowel disease.
In particular, this report provides the following analysis -
- Provides an introduction to immunology therapeutics, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications and prognosis.
- Provides an overview of the immunology therapeutics marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
- Analyzes the immunology therapeutics pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.
- Provides forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
- Assesses the company landscape in immunology therapeutics, with an analysis of the key players, the types of company involved in this therapy area and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenues.
- Analyses trends in co-development and licensing deals relating to therapeutic products in immunology.
Companies mentioned in this report: AbbVie, Johnson & Johnson, Roche, Amgen, Pfizer, Celgene, Takeda, Novartis, Eli Lilly, Bristol-Myers Squibb, UCB, Merck & Co, Regeneron, GlaxoSmithKline, Mallinckrodt, Astellas, Sanofi, Shire, Mitsubishi Tanabe, AstraZeneca, Eisai, Ono, Allergan, Biogen, Swedish Orphan Biovitrum, Valeant, Daiichi Sankyo.Scope
Reasons to buy
- Global revenues for the immunology market are forecast to grow at a compound annual growth rate of 3.63%, from $57.7 billion in 2015 to $74.1 billion in 2022.
- Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The immunological disorders pipeline is large and diverse, and contains 2,054 products. How does the composition of the pipeline compare with that of the existing market?
- What molecular targets and molecule types are most commonly being trialed in pipeline products in the key indications?
- Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the immunology market set to change?
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
- Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the immunological disorders pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the immunology market, globally and across the key players and product types
- Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various immunological disorders.
- Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals